Huasun(SZ:000790)2022-08-30 16:00Financial Performance - The company's operating revenue for the first half of 2022 was CNY 407,389,669.31, representing a 20.59% increase compared to CNY 337,822,043.33 in the same period last year[21]. - The net profit attributable to shareholders decreased by 23.09% to CNY 17,369,678.22 from CNY 22,583,211.17 in the previous year[21]. - The net profit after deducting non-recurring gains and losses fell by 42.83% to CNY 15,947,634.58 compared to CNY 27,892,749.03 in the same period last year[21]. - The basic earnings per share decreased by 24.04% to CNY 0.0278 from CNY 0.0366 in the same period last year[21]. - The weighted average return on net assets was 1.80%, down from 2.31% in the previous year[21]. - The company achieved a total revenue of 407.39 million yuan, representing a year-on-year growth of 20.59%[36]. - The net profit attributable to shareholders was 17.37 million yuan, a decline of 23.09% year-on-year, largely due to decreased sales in the pharmaceutical sector[37]. - The company reported a net profit margin improvement, with undistributed profits rising from CNY 182,259,993.72 to CNY 199,629,671.94, an increase of 9.5%[139]. - The net profit for the first half of 2022 was CNY 15,271,333.98, down 32.8% from CNY 22,737,455.22 in the same period of 2021[146]. - The operating profit for the first half of 2022 was CNY 19,004,077.48, a decline of 31.6% from CNY 27,844,729.92 in the first half of 2021[145]. Cash Flow and Investments - The net cash flow from operating activities improved significantly to CNY 37,811,459.99, a 178.70% increase from a negative CNY 48,044,082.93 in the previous year[21]. - Cash inflow from operating activities was CNY 390,256,922.38 in the first half of 2022, compared to CNY 368,152,305.12 in the same period of 2021[150]. - Total cash outflow from investment activities reached ¥205,371,091.69, resulting in a net cash flow from investment activities of -¥200,891,423.69, compared to -¥99,244,742.63 in the previous year[152]. - Cash inflow from financing activities amounted to ¥79,170,000.00, while cash outflow totaled ¥64,479,701.63, leading to a net cash flow from financing activities of ¥14,690,298.37, up from ¥956,394.36 in 2021[152]. - The total cash and cash equivalents at the end of the period were ¥125,559,704.08, down from ¥232,839,826.61 at the end of the first half of 2021[152]. Business Segments and Operations - The pharmaceutical business revenue was 171.62 million yuan, a decrease of 30.08% year-on-year, primarily due to the impact of COVID-19 on major sales regions[36]. - The steel structure business saw a revenue increase of 76.94%, reaching 149.52 million yuan, driven by enhanced team incentives and resource integration[36]. - The newly acquired blue light mineral water beverage business contributed an additional revenue of 73.36 million yuan[36]. - The health industry segment saw a remarkable revenue increase of 2,354.00%, reaching CNY 71,086,909.03, compared to CNY 2,896,773.28 in the same period last year[47]. - The company is expanding its health product offerings by acquiring mineral water resources to diversify its business and reduce risks associated with the pandemic[72]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,406,100,454.29, up 4.07% from CNY 1,351,112,420.20 at the end of the previous year[21]. - The net assets attributable to shareholders decreased by 0.98% to CNY 966,940,039.73 from CNY 976,494,790.70 at the end of the previous year[21]. - Current liabilities increased to CNY 377,130,317.46, compared to CNY 327,550,537.98, marking a rise of 15.1%[139]. - Non-current liabilities totaled CNY 60,157,146.38, up from CNY 42,125,873.69, indicating a significant increase of 42.8%[139]. - The total liabilities at the end of the period were CNY 1,872,950, reflecting the company's leverage position[162]. Corporate Governance and Shareholder Relations - The company plans not to distribute cash dividends or issue bonus shares[5]. - The company has maintained its board and management personnel without changes during the reporting period, ensuring stability in governance[78]. - The company has a systematic approach to environmental monitoring, including third-party assessments of wastewater and air emissions every six months[88]. - The company has maintained a strong commitment to shareholder rights, ensuring timely and accurate information disclosure and facilitating shareholder participation in decision-making processes[91]. - Employee rights are prioritized, with compliance to labor laws, timely salary payments, and regular health checks to ensure a safe working environment[92]. Research and Development - The company is focusing on the development of new products based on existing advantages in therapeutic areas, particularly for its core products[33]. - The company aims to enhance its R&D capabilities by collaborating with domestic and international research institutions to adapt to changing market demands and improve product acceptance[73]. - Research and development expenses increased to CNY 13,364,976.44 in the first half of 2022, up 36.5% from CNY 9,818,160.05 in the first half of 2021[145]. Environmental and Social Responsibility - The company has achieved compliance with environmental standards, with all major pollutants from wastewater and exhaust gases meeting regulatory limits, including COD at 129 mg/L against a limit of 500 mg/L and VOCs at 2.29 mg/m³ against a limit of 60 mg/m³[83][84]. - The company has received recognition for its environmental efforts, including being rated as a "Good Environmental Enterprise" by the Sichuan Provincial Department of Ecology and Environment for 2021[90]. - The company emphasizes its commitment to social responsibility and actively supports education and scientific research in China[93]. - The company donated 3 million RMB to Chengdu University of Traditional Chinese Medicine for the "Double First-Class" initiative in October 2021, ensuring effective use of funds for talent cultivation and technology research[93]. Acquisitions and Investments - The company acquired 100% equity in Sichuan Blue Light Mineral Water Co., Ltd. for 61,000,000.00 yuan, effective January 1, 2022[55]. - The company also acquired 100% equity in Chengdu Yuanhong Mineral Water Co., Ltd. for 33,200,000.00 yuan, effective June 30, 2022[55]. - The company reported an investment amount of 108,200,000.00 yuan for the reporting period, a significant increase of 9,362.32% compared to 1,143,483.00 yuan in the same period last year[53]. Risks and Challenges - The company has identified risks related to drug price reductions due to government policies, which could adversely affect sales and overall operations[69]. - The company emphasizes a cautious approach to new business development, prioritizing risk control and market demand alignment[74].